Four years after he joined the New York drugmaker’s ranks in the wake of the unexpected fallout from the coronavirus pandemic, Pfizer Chief Financial Officer Dave Denton will soon bid farewell to the pharmaceutical industry and pivot back to the consumer goods industry.
The baton will be passed to Denton on August 15, Pfizer announced Thursday. The CFO will highlight “opportunities for non-pharmaceutical professionals in the consumer goods space,” and Cécile Guegan, vice president of finance for Pfizer’s global biopharmaceutical business, will assume the interim role of finance director. Pfizer also noted that it has begun an internal and external search for a permanent successor for the position.
CEO Albert Bourla called Denton a “stable and reliable steward of Pfizer’s financial health” and pointed to his leadership in “some of the most significant business transactions in our company’s recent history,” including the acquisitions of Seagen, Biohaven and Metsala, which “will serve Pfizer well for years to come.”
“We wish him all the best as he returns to the consumer goods industry,” Bourla said in a company release.
As for Denton, the outgoing CFO said, “It has been an honor and privilege to work with Albert at Pfizer, an iconic and purpose-driven company, at such a significant time in its history,” adding that Pfizer is “in great hands.”
His interim successor, Guegan, has 20 years of experience at Pfizer and was credited in the release with integrating Seegen into a larger company in 2024.
Pfizer stock fell 3.5% Thursday morning on news of Denton’s departure.
Prior to joining Pfizer, Mr. Denton’s career was rooted in the consumer goods sector, with the executive serving as CFO of CVS Health for nearly 20 years and three years in the same role at Lowe’s. Upon joining Pfizer, he was credited with playing a “pivotal role” in the transformation of CVS into a healthcare-focused pharmacy through its merger with Caremark.
He joined Pfizer in May 2022 in a major role, replacing Frank D’Amelio, who served as chief financial officer (CFO) for 15 years, who resigned from the company. When Mr. D’Amelio left in 2021, the company had secured more than $24 billion from COVID-19 relief funds, leaving Mr. Denton with the task of leveraging the company’s new major funding stream.
Just one week after Denton officially took over, his dealmaking legacy at Pfizer took shape through the $11.6 billion acquisition of the company’s migraine partner Biohaven Pharmaceuticals, giving the company full access to migraine drug Nurtec and the broader CGRP portfolio.
The biggest deal under Denton’s leadership came the following year with Pfizer’s $43 billion acquisition of antibody-drug conjugate (ADC) drug company Seagen, which enabled Pfizer to incorporate key oncology drugs Padceb, ADCETRIS, and others into its commercial and R&D portfolio.
Meanwhile, Pfizer’s latest M&A plan, announced in the form of a $10 billion acquisition of Metsa in 2025, ended a public spat with Novo Nordisk over an acquisition target for obesity patients. Pfizer’s acquisition efforts reflect the company’s renewed efforts to advance obesity research and development. Mr. Denton’s annual performance award was counted as $9.6 million in 2025 compensation, exceeding his 2024 salary package of $8.1 million.
After hitting new highs in coronavirus-related revenues, Pfizer and Dentons have spent the last year responding and preparing for even lower revenues ahead.
The company forecasts sales of $59.5 billion to $62.5 billion in 2026, down from $62.6 billion in 2025, highlighting the impact of coronavirus sales declines, the patent cliff and changes in U.S. drug pricing policy.
To reduce expenses, Pfizer is implementing a radical cost readjustment program that aims to reduce net costs by up to $7.7 billion by 2027.
